Nintedanib treatment for bleomycin-induced lung injury - First report

Dina Rnjak; Martina Batarilo Hađar; Dubravka Pelicarić; Tea Vukić; Mateja Janković Makek; Miroslav Samaržija; Ana Hećimović

doi:10.1016/j.rmcr.2023.101921

Nintedanib treatment for bleomycin-induced lung injury - First report

Respir Med Case Rep. 2023 Sep 27:46:101921. doi: 10.1016/j.rmcr.2023.101921. eCollection 2023.

Authors

Dina Rnjak¹, Martina Batarilo Hađar¹, Dubravka Pelicarić¹, Tea Vukić¹, Mateja Janković Makek^{1

2}, Miroslav Samaržija^{1

2}, Ana Hećimović^{1

2}

Affiliations

¹ University Hospital Zagreb, Clinical Center for Pulmonary Diseases Jordanovac, Jordanovac 104, Zagreb, Croatia.
² University of Zagreb, School of Medicine, Šalata 2, Zagreb, Croatia.

Abstract

Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients. The optimal treatment for bleomycin lung toxicity has not been established and no clinical trials have been performed. Here we present first successful case report of nintedanib therapy in a patient with bleomycin-induced lung injury (BILI). The prevention, early diagnosis, and management of bleomycin pulmonary toxicities are essential, clinical trials are needed in this area.

Keywords: Bleomycin; Lungs; Nintedanib.

Publication types

Case Reports